Avacta selects potential tumour treatment for preclinical development Read More
AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers Read More
LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony Read More
Abingdon Health plunges after Avacta stops selling Covid-19 test Read More
AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests Read More
Avacta shares drop as Covid tests show reduced sensitivity to Omicron Read More
LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures Read More
AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins Read More
Avacta shares up as flow tests receive CE mark for self-test use Read More
Avacta confirms lateral flow tests can detect Omicron variant Read More
IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US Read More
Avacta and Novacyt await UK regulatory approval for Covid-19 tests Read More
Avacta hails "transformative" first half despite widening loss Read More
Avacta sees pre-clinical development milestone in LG Chem partnership Read More
UK earnings, trading statements calendar - next 7 days Read More
IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO Read More
IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board Read More
Avacta doses first patient in chemotherapy medication trial Read More
IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts Read More
AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down Read More
